Synthesis and characterization of curcumin-encapsulated loaded on carboxymethyl cellulose with docking validation as α-amylase and α-glucosidase inhibitors-Reference-Cited by-同舟云学术

Synthesis and characterization of curcumin-encapsulated loaded on carboxymethyl cellulose with docking validation as α-amylase and α-glucosidase inhibitors

Published:2024-09-06 Issue: Volume: Page:
ISSN:1899-4741
Container-title:Polish Journal of Chemical Technology
language:en
Short-container-title:

Author:

Almehizia Abdulrahman A.¹,Al-Omar Mohamed A.¹,Al-Obaid Abdulrahman M.¹,Naglah Ahmed M.¹,Bhat Mashooq A.¹,Ghabbour Hazem A.²³,Khatab Tamer K.⁴,Hassan Ashraf S.⁴

Affiliation:

1. Department of Pharmaceutical Chemistry, College of Pharmacy , King Saud University , P.O. Box 2457, Riyadh 11451 , Saudi Arabia

2. School of health and biomedical sciences , RMIT University , Melbourne 3083 , Australia

3. Department of Medicinal Chemistry, Faculty of Pharmacy , University of Mansoura , Mansoura , Egypt

4. Organometallic and Organometalloid Chemistry Department, National Research Centre , Dokki 12622, Cairo , Egypt

Abstract

Abstract In reaction to the expanding predominance of diabetes mellitus, curcumin nanoparticles stacked on carboxymethyl cellulose (CMC) composite were effectively synthesized, characterized, and examined utilizing UV/Vis and FTIR spectroscopy combined with transmission electron microscopy (TEM). The bioactivity of curcumin (Cur), carboxymethyl cellulose (CMC), and curcumin nanoparticles stacked with carboxymethyl cellulose (CUR-CMC) was tried through atomic docking approval as an α-amylase and α-glucosidase inhibitor. The conclusion illustrated that the curcumin-supported CMC is more potent than CUR itself self the validation presented is compared with acarbose as a reference molecule and then CUR-CMC can presented as promising in curing hyperglycemia by decreasing the absorption of glucose.

Publisher

Walter de Gruyter GmbH

Link

https://www.sciendo.com/pdf/10.2478/pjct-2024-0031

Reference38 articles.

1. Sugandh, F., Chandio, M., Raveena, F., Kumar, L., Karishma, F., Khuwaja, S., Memon, U.A., Bai, K., Kashif, M., Varrassi, G., Khatri, M. & Kumar, S. (2023). Advances in the Management of Diabetes Mellitus: A Focus on Personalized Medicine. Cureus 15(8), e43697. DOI: 10.7759/cureus.43697.

2. Rosengren, A. & Dikaiou, P. (2023). Cardiovascular outcomes in type 1 and type 2 diabetes. Diabetologia 66, 425–437. DOI: 10.1007/s00125-022-05857-5.

3. Joshua, S.R. Shin, S. Lee, J.H. & Kim, S.K. (2023). Health to Eat: A Smart Plate with Food Recognition, Classification, and Weight Measurement for Type-2 Diabetic Mellitus Patients’ Nutrition Control. Sensors 23(3), 1656. DOI: 10.3390/s23031656.

4. Padhi, S. Nayak, A.K. & Behera, A. (2020). Type II diabetes mellitus: a review on recent drug based therapeutics. Biomed. Pharmacother. 131, 110708. DOI: 10.1016/j.biopha.2020.110708.

5. Kwon, S., Kim, Y.C., Park, J.Y., Lee, J., An, J.N., Kim, C.T., Oh, S., Park, S., Kim, D.K., Oh, Y.K. & Kim, Y.S. (2020). The long-term effects of metformin on patients with type 2 diabetic kidney disease. Diabetes Care 43(5), 948–955. DOI: 10.2337/dc19-0936.